An orally bioavailable heterobifunctional IRAK4 degrader (KT-474) in phase I clinical trials (NCT04772885) could treat patients with various immuno-inflammatory diseases, such as rheumatoid arthritis, atopic dermatitis or hidradenitis suppurativa. Here, IRAK4 is linked to atopic eczema.